Neutrophils in Rectal Cancer: The Sarandria Score - a New Clinical Prognostic and Predictive Score and Further Proof of Identifying Rectal Cancer as a Separate Clinical and Pathological Entity from Colon Cancer | Chapter 07 | New Horizons in Medicine and Medical Research Vol. 7

 This study aims to provide fresh insight on neutrophils' role in rectal cancer while also emphasising the differences between rectal and colon cancer, as well as strengthen and emphasise a new clinical prognostic and predictive scoring system (Sarandria Score). This research offers a new scoring method for patients with stage III rectal cancer that may be used as an inclusion criterion as well as a predictive and prognostic scoring system.

Background: Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second most commonly diagnosed cancer in women, making it a serious public health concern. Various studies have discovered significant disparities in adjuvant therapy responsiveness and prognosis dependent on the primary site of CRC (right-sided colon, left-sided colon, rectum). A larger density of tumor-associated neutrophils (TANs) has previously been linked to a better response to 5-FU-based treatment in stage III CRC patients.

Results: This chapter assesses the current state of knowledge on neutrophil participation in colorectal cancer, including a novel finding on the role of neutrophils in rectal cancer discovered by Dr. Nicola Sarandria. When chemotherapeutic drugs are present, it covers a number of variables that point to neutrophils playing an anti-tumor role in rectal cancer (such as 5-fluorouracil). The clinical significance of TANs was studied, as well as if it altered depending on the location of the primary CRC (right-sided colon, left-sided colon, rectum).

Conclusions: This chapter introduces the Sarandria Score, a new clinical prognostic and predictive scoring system for rectal cancer patients with intratumoral neutrophilic infiltration, as well as the possibility of a new inclusion criteria for Stage III rectal cancer patients receiving 5-FU therapy based on this infiltrate. Higher TANs densities were connected to greater disease-free survival (DFS) in rectal cancer patients treated with 5-FU, according to the author's medical degree thesis (while it was inversely related in patients without 5-FU therapy). This adds to the growing body of data showing colorectal cancer can be separated into two types: colon and rectal cancer.

Author(S) Details

Nicola Sarandria
University of Padova, Padova, Italy.

View Book:- https://stm.bookpi.org/NHMMR-V7/article/view/6665